Items where Author is "Drzewiecka, Aleksandra"
 | Up a level |
Group by: Item Type | No Grouping
Number of items: 1.
Mancuso, Maria Elisa 
ORCID: https://orcid.org/0000-0002-7113-4028
Castaman, Giancarlo ORCID: https://orcid.org/0000-0003-4973-1317
Pochopien, Michal
Aballéa, Samuel
Drzewiecka, Aleksandra ORCID: https://orcid.org/0000-0003-3396-8571
Hakimi, Zalmai ORCID: https://orcid.org/0000-0001-5835-8599
Nazir, Jameel
et al.
ORCID: https://orcid.org/0000-0002-7113-4028
Castaman, Giancarlo ORCID: https://orcid.org/0000-0003-4973-1317
Pochopien, Michal
Aballéa, Samuel
Drzewiecka, Aleksandra ORCID: https://orcid.org/0000-0003-3396-8571
Hakimi, Zalmai ORCID: https://orcid.org/0000-0001-5835-8599
Nazir, Jameel
et al.
Mancuso, Maria Elisa ORCID: https://orcid.org/0000-0002-7113-4028, Castaman, Giancarlo ORCID: https://orcid.org/0000-0003-4973-1317, Pochopien, Michal, Aballéa, Samuel, Drzewiecka, Aleksandra ORCID: https://orcid.org/0000-0003-3396-8571, Hakimi, Zalmai ORCID: https://orcid.org/0000-0001-5835-8599, Nazir, Jameel and Fatoye, Francis ORCID: https://orcid.org/0000-0002-3502-3953
(2022)
Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.
Journal of Medical Economics, 25 (1).
pp. 1068-1075.
ISSN 1369-6998
ORCID: https://orcid.org/0000-0002-7113-4028, Castaman, Giancarlo ORCID: https://orcid.org/0000-0003-4973-1317, Pochopien, Michal, Aballéa, Samuel, Drzewiecka, Aleksandra ORCID: https://orcid.org/0000-0003-3396-8571, Hakimi, Zalmai ORCID: https://orcid.org/0000-0001-5835-8599, Nazir, Jameel and Fatoye, Francis ORCID: https://orcid.org/0000-0002-3502-3953